Huayi Celebrates Milestone Achievement with DMF Registration for PSMA-11 Precursor

We proudly announces a significant milestone with the successful acquisition of Drug Master File (DMF) registration for the PSMA-11 precursor. This achievement underscores Huayi's unwavering commitment to upholding the highest standards in the development and production of radiopharmaceuticals.

The achievement of DMF registration for the PSMA-11 precursor stands as a testament to the dedication and expertise of our exceptional team, underscoring its relentless pursuit of quality and innovation.

As Huayi continues to pioneer advancements in radiopharmaceutical research and development, We remains dedicated to our mission of improving healthcare outcomes through innovative solutions. This milestone marks a new chapter in Huayi's journey, and we are poised to make  contributions to the evolving landscape of medical diagnostics and treatment.